Key Benefits:
Minister of the City, Youth and Sports,
Vu le Sport codeincluding article L. 232-26;
Considering the opinion of the French Doping Agency dated 22 October 2014,
Stop it!
Can be subject to the criminal sanctions mentioned in I of Article L. 232-26 of the Sports Code the detention, without duly justified medical reason, of a prohibited substance or methods listed in the last paragraph of Article L. 232-9, for which Appendix 1 to the international convention referred to in Article L. 230-2 provides for the possibility of reduced sanctions only in the event of exceptional circumstances. These prohibited substances and methods are listed below:
Prohibited substances
I. - Anabolic agents:
1° Androgenic anabolic steroids (SAA):
(a) Exogenous SAA, including:
1-androstènediol (5α-androst-1-ène-3β,17β-diol); 1-androstènedione (5α-androst-1-ène-3,17-dione) ; bolandiol (estr-4-ène-3β,17β-diol); bolasterone; boldenone; boldione (androsta-1,4-diène-3,17-dione); calusterone; enclosurebol; danazol ( [1,2] oxazolo [4',5' : 2,3] pregna-4-ène-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17α-methyl-5α-androst-2-ène-17β-ol); drostanolone; ethylestrenol (19-norprégna-4-ène-17α-ol) ; fluoxymesterone ; formationbolone ; ferazabol (17α-methyl [1,2.5] oxadiazolo [3',4': 2,3] -5α-androstane-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-ène-3-one) ; mestanolone ; mesterolone ; metandinone (17β-hydroxy-17α-methylandrosta-1,4-diène-3-one); meternolone; methandriol; methasterone (17β-hydroxy-2α, 17α-dimethy1-5α-androstane-3-one); methyldenolon (17β-hydroxy-17α-methylestra-4,9- diene-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-ène-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β- hydroxy-17α-methylestra-4,9,11-trine-3-one); mibolone; nandrolone; 19-norandrostendione (estr-4-ene- 3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterrone; oxymetholone; prostanozol (17β [(tétrahydropyrane-2-yl) oxy] -1'H-pyrazolo [3,4: 2,3] -5α-androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-ène-3-one) ; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-prégna-4,9,11-triène-3-one); trenbolone (17β-hydroxyestr-4,9,11- trine-3-one); and other substances having a similar chemical structure or a (des) biological effect (s) similar (s).
(b) Endogenous SAA by exogenous administration:
androstènediol (androst-5-ène-3β,17β-diol); androstènedione (androst-4-ène-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA, 3β-hydroxyandrost-5- ène-17-one) ; testosterone ; and the following metabolites and isomers, including without limitation: 5α-androstane-3α,17α-diol ; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane- 3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstènediol (androst-4-ène- 3β,17β-diol); 5-androstènedione (androst-5-ène-3,17-dione) ; epi-dihydrotestosterone ; epitestosterone ; elo-cholanolone ; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 7α-hydroxy-DHEA; 7β- hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-norétiocholanolone.
2° Other anabolic agents, including but not limited to:
Clenbuterol, selective modulators of androgenic receptors (SARMs), tibolone, zéranol, zilpatrol.
II. - Peptide hormones, growth factors and related substances:
The following substances and other substances with a similar chemical structure or similar biological effects(s):
1° Energizing agents of erythropoiesis [e.g. erythropoetin (EPO), darbepoetin (dEPO), metoxy polyethylene glycol-epoetin beta (CERA), petginesatide (Hematide), stabilizers and activators of factors inductible by the hypoxia (HIF) (par)
2° Gonadotrophine chorionique (CG) and luteinizing hormone (LH), and their factors of liberation, in male athletes only;
3° Corticotrophines and their factors of liberation;
4° Growth Hormone (GH) and its liberation factors, and the growth factor similar to insulin-1 (IGF-1); the following growth factors: growth factor derived from platelets (PDGF), endothelial vascular growth factor (VEGF), hepatocyte growth factor (HGF), fibroblastic growth factors (FGF), mechanical growth factors (MGF), as well as any other growth factor influencing, in muscle, tendon or ligament, synthetic/degradation prote
III. - Hormonal and metabolic modulators:
1° Modifying agents of (s) the function (s) of myostatin, including without limitation: myostatin inhibitors;
2° Metabolic modulators:
(a) Insulins;
(b) The receptor agonists activated by the proliferators of the δ peroxysomes (PPARδ) (e.g. GW 1516) and the agonists of the PPARδ-protein kinase axis activated by the AMPK (e.g. AICAR).
IV. - Stimulants:
Adrafinil, afepramone, amiphenazol, amphetamine, amphetamine, benfluorex, benzylpipérazine, bromantan, clobenzorex, cocaine, cropropamide, fencamine, fenetylline, fenfluramine, fenproporex, fonturacétam [4-phenylpira
Prohibited methods
I. - Handling blood or blood components:
1° Administration or reintroduction of any amount of autologous, allogenic (homologist) or heterogeneous blood, or red blood cells of any origin in the circulatory system;
2° Artificial improvement in the consumption, transport or release of oxygen, including, but not limited to, perfluorinated chemicals, efaproxiral (RSR13) and modified hemoglobin products (e.g. blood substitutes based on hemoglobin, reticulated hemoglobin products), but excluding oxygen supplementation;
3° Any intravascular manipulation of blood or blood component(s) by physical or chemical methods.
II. - Chemical and physical manipulation:
1° Falsification or attempted falsification, with the aim of altering the integrity and validity of samples collected during doping control. This category includes, without limitation, the substitution and/or alteration of urine (e.g. proteases);
2° Intravenous infusions and/or injections of more than 50 ml per six-hour period, except those legitimately received in hospital admissions or in clinical examinations.
III. - Genetic doping:
1° Transfer of nucleic acid polymers or nucleic acid analogs;
2° Use of normal or genetically modified cells.
The order of June 5, 2012 setting out the list of substances and methods for which sports detention is prohibited under section L. 232-26 is repealed.
The Sports Director is responsible for the execution of this Order, which will be published in the Official Journal of the French Republic.
Done on 24 November 2014.
For the Minister and by delegation:
The Director of Sports,
T. Mosimann
